TrialNature communications2021
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
Synne Jenum et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
47 papers cite it
this papertrialcites it